RESEARCH · TIRZEPATIDE · CARDIOVASCULAR RISK FACTORS
Tirzepatide and Cardiovascular Risk Factors: Blood Pressure, Lipids, Heart Rate and Biomarkers Across SURPASS and SURMOUNT
PurixLab's Tirzepatide 10mg is a research vial of the dual GIP and GLP-1 receptor agonist. Our earlier articles cover a research overview, body composition, liver fat and heart failure, withdrawal and weight regain and kidney outcomes and SURPASS-CVOT. This article follows the cardiovascular risk factors measured along the way: blood pressure, lipids and lipoproteins, heart rate and circulating biomarkers. These are published findings from clinical research under medical supervision and from animal studies; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.
Risk factors are not events
Risk factors change within months, while cardiovascular events take years to accumulate. Before outcome trials reported, a pre-specified meta-analysis pooled the seven SURPASS trials lasting at least 26 weeks: 4,887 participants on tirzepatide and 2,328 controls, of whom 142 had at least one major adverse cardiovascular event. The hazard ratio was 0.80 (95% CI, 0.57-1.11), and the authors concluded that tirzepatide did not increase cardiovascular risk [1]. The risk-factor data below should be read with that distinction in mind.
Blood pressure
- Obesity without diabetes. In SURMOUNT-1, blood pressure fell quickly over the first 24 weeks and then levelled off, giving net reductions at 72 weeks of 6.8 mm Hg systolic and 4.2 mm Hg diastolic versus placebo. At week 72, 58.0% of participants on tirzepatide and 35.2% on placebo had normal blood pressure. In a mediation analysis, weight loss explained 68% of the systolic and 71% of the diastolic reduction, and low blood pressure adverse events were infrequent but more common with tirzepatide [2]. A substudy using ambulatory monitoring, published as a research letter, also reported lower ambulatory blood pressure [3].
- Type 2 diabetes. Across SURPASS-1 to -5, the difference in systolic change at 40 weeks between the highest tirzepatide arm and comparators ranged from 3.1 to 11.5 mmHg. The reductions were mostly mediated by weight loss, but in SURPASS-4, which enrolled people with established cardiovascular disease, weight-loss independent effects explained 33% to 57% of the difference versus insulin glargine. The pooled correlation between weight change and systolic change was weak (r = 0.18 to 0.22), reductions did not depend on background antihypertensive medication, and participants starting below 122 mmHg saw no further fall [4].
- Japanese participants. In a post hoc analysis of 548 SURPASS J-mono participants, correlations between weight change and systolic blood pressure were weak to moderate (r = 0.19 to 0.41) [5].
- Adverse event data. A 2026 meta-analysis of 32 randomised trials with 47,332 participants linked tirzepatide to fewer hypertension-related events (RR = 0.40) but more hypotension-related events (RR = 2.45), while semaglutide showed no significant association with either [6].
An animal study points the other way. In stroke-prone spontaneously hypertensive rats, a lean model, 4 weeks of tirzepatide raised mean blood pressure (197.4 vs 153.7 mmHg against pair-fed controls at day 28) and heart rate, with sympathetic activation, left ventricular hypertrophy and fibrosis [7]. The authors describe the cardiovascular actions as context-dependent.
Lipids and lipoproteins
A 2023 meta-analysis of seven randomised trials found that tirzepatide lowered total cholesterol, LDL cholesterol and triglycerides and raised HDL cholesterol, with total cholesterol falling by a median of 3.76% to 5.93% across the three maintenance levels [8]. Phase 2 samples gave more detail. Over 26 weeks, tirzepatide lowered apoB and apoC-III and raised preheparin lipoprotein lipase, and the two higher arms reduced large triglyceride-rich lipoprotein particles, small LDL particles and a lipoprotein insulin resistance score compared with both placebo and dulaglutide. Change in apoC-III, not body weight, was the best predictor of the fall in triglycerides, explaining up to 22.9% of its variability [9]. A metabolomic analysis of 259 participants found falls in branched-chain amino acids and related catabolites that were larger than with dulaglutide [10].
The relationship with weight loss differs by measure. In 1605 SURMOUNT-1 participants on tirzepatide, triglycerides, HDL, LDL and non-HDL cholesterol improved mainly once weight loss exceeded 10%, whereas insulin resistance and HbA1c improved even with modest weight loss, and those losing at least 35% had systolic changes of up to 14.2 mm Hg [11].
Heart rate
Heart rate moves in the opposite direction. A network meta-analysis of eight articles in type 2 diabetes, with baseline heart rates of 65.2 to 75.7 beats per minute, found a larger rise with tirzepatide than with combined controls (mean difference 1.82) and than with GLP-1 receptor agonists (2.29). The increase was graded across the three arms, with the highest arm 2.53 beats per minute above the lowest [12].
Inflammatory, endothelial and other biomarkers
- Phase 2 biomarkers. At 26 weeks the two higher arms lowered YKL-40, ICAM-1, leptin and growth differentiation factor 15 from baseline. YKL-40, hsCRP and ICAM-1 fell within 4 weeks, while interleukin 6, VCAM-1, GlycA and NT-proBNP did not change [13].
- SURMOUNT-1 biomarkers. In 392 participants sampled to week 72, hsCRP fell by 36.9% to 54.6% across the three arms versus placebo and leptin by 44.4% to 61.4%, adiponectin rose by 21.1% to 47.7%, and E-selectin and PAI-1 antigen fell, while fibrinogen, tPA antigen and thrombomodulin showed no consistent change [14].
- Composite risk measures. In 2461 SURMOUNT-1 participants without atherosclerotic disease, baseline median predicted 10-year risk was low (1.5% to 1.6%); its relative change by week 72 was -23.5% to -16.4% with tirzepatide versus 12.7% with placebo [15]. Across SURPASS, metabolic syndrome prevalence fell from 67-88% at baseline to 38-64% with tirzepatide versus 64-82% with comparators [16], and 32-38% versus 2-8% of SURMOUNT participants reached a combined weight, systolic and non-HDL cholesterol endpoint [17].
Reading this evidence critically
- Mostly post hoc. Nearly all of these analyses are secondary or post hoc, and the SURMOUNT-1 weight-reduction analysis was funded by the manufacturer [11].
- Weight is the main driver. Most of the blood pressure change is explained by weight loss, though not all of it [2,4].
- Predicted risk is not observed risk. Risk scores and biomarkers are surrogates [15,1].
What remains open
- Whether the modest rise in heart rate matters over years.
- Why a lean hypertensive rat model showed higher blood pressure.
- Which biomarker changes are independent of weight loss.
Tirzepatide 10mg at PurixLab
Tirzepatide 10mg: a labelled lyophilized research vial with 10mg per vial, C$129 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/tirzepatide-10mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591-598. PubMed 35210595 · PMC8938269 · doi:10.1038/s41591-022-01707-4
- Krumholz HM, de Lemos JA, Sattar N, et al. Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial. Heart. 2024;110(19):1165-1171. PubMed 39084707 · PMC11420724 · doi:10.1136/heartjnl-2024-324170
- de Lemos JA, Linetzky B, le Roux CW, et al. Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m2: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy. Hypertension. 2024;81(4):e41-e43. PubMed 38314555 · PMC10956672 · doi:10.1161/HYPERTENSIONAHA.123.22022
- Lingvay I, Mosenzon O, Brown K, et al. Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovasc Diabetol. 2023;22(1):66. PubMed 36964557 · PMC10039543 · doi:10.1186/s12933-023-01797-5
- Mimura H, Oura T, Chin R, et al. Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J-mono trial. J Diabetes Investig. 2025;16(5):807-816. PubMed 39891527 · PMC12057373 · doi:10.1111/jdi.14395
- Chen QX, Zhou XY, Wu Q, et al. Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis. Endocrine. 2026;91(1):275. PubMed 42603240 · doi:10.1007/s12020-026-04757-7
- Ono Y, Shinohara K, Nakashima H, et al. Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats. Hypertens Res. 2026;49(6):1924-1938. PubMed 41992025 · doi:10.1038/s41440-026-02632-6
- Kanbay M, Copur S, Siriopol D, et al. Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2023;25(12):3766-3778. PubMed 37700437 · doi:10.1111/dom.15272
- Wilson JM, Nikooienejad A, Robins DA, et al. The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes Obes Metab. 2020;22(12):2451-2459. PubMed 33462955 · PMC7756479 · doi:10.1111/dom.14174
- Pirro V, Roth KD, Lin Y, et al. Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes. J Clin Endocrinol Metab. 2022;107(2):363-378. PubMed 34608929 · doi:10.1210/clinem/dgab722
- Linetzky B, Sattar N, Verma S, et al. Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide. Ann Intern Med. 2025;178(8):1095-1105. PubMed 40550133 · doi:10.7326/ANNALS-24-02623
- Yang Y, He L, Liu P, et al. Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis. Diabetes Obes Metab. 2024;26(2):548-556. PubMed 37860884 · doi:10.1111/dom.15342
- Wilson JM, Lin Y, Luo MJ, et al. The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis. Diabetes Obes Metab. 2022;24(1):148-153. PubMed 34542221 · PMC9292792 · doi:10.1111/dom.14553
- Sattar N, Linetzky B, Ruotolo G, et al. Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis. J Am Coll Cardiol. 2026;88(6):652-666. PubMed 42233927 · doi:10.1016/j.jacc.2026.04.044
- Hankosky ER, Wang H, Neff LM, et al. Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis. Diabetes Obes Metab. 2024;26(1):319-328. PubMed 37932236 · doi:10.1111/dom.15318
- Nicholls SJ, Tofé S, le Roux CW, et al. Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program. Cardiovasc Diabetol. 2024;23(1):63. PubMed 38341541 · PMC10859014 · doi:10.1186/s12933-024-02147-9
- Sattar N, Srinath R, García-Pérez LE, et al. Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials. PLoS One. 2026;21(8):e0345032. PubMed 42594122 · PMC13472364 · doi:10.1371/journal.pone.0345032